Asia-Pacific Internal Neurostimulation Devices Market, By Product Type (Spinal Cord Stimulation (SCS), Deep Brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation and Gastric Electric Stimulation), Distribution Channel (Direct Tender and Third Party Service Provider) - Industry Trends and Forecast to 2029.
Asia-Pacific Internal Neurostimulation Devices Market Analysis and Insights
The rise in demand for internal neurostimulation devices as add-on therapy, increase in prevalence and incidence of neurological diseases, increased funding for the neurostimulation devices, technological advancements in the internal neurostimulation devices and rise in product approvals are expected to drive market growth.
The strategic initiatives by market players and increased funding by public and private market players for internal neurostimulation devices are expected to create opportunities for market growth. However, the lack of skilled and trained experts in internal neurostimulation devices is expected to restrain the segment's growth. The availability of alternate imaging devices is expected to challenge the market growth.
Data Bridge Market Research analyzes that the Asia-Pacific internal neurostimulation devices market will grow at a CAGR of 16.4% and USD 3,890.15 Million during the forecast period of 2022 to 2029.
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2024)
|
|
Quantitative Units
|
Revenue in USD Million, Pricing in USD
|
|
Segments Covered
|
By Product Type (Spinal Cord Stimulation (SCS), Deep Brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation and Gastric Electric Stimulation), Distribution Channel (Direct Tender and Third Party Service Provider)
|
|
Countries Covered
|
China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and the Rest of Asia-Pacific
|
|
Market Players Covered
|
Medtronic, LivaNova PLC, Abbott, Microsemi (a subsidiary of Microchip Technology Inc.), Boston Scientific Corporation, Integer Holdings Corporation, GIMER Medical, Bionic Vision Technologies., NEVRO CORP., Valencia Technologies, CIRTEC, Sequana Medical NV, BIOINDUCTION, ONWARD, Axonics, Inc., among others
|
Market Definition
An internal neurostimulation device is a surgically placed device. It delivers mild electrical signals to the epidural space near your spine through one or more thin wires called leads. Neurostimulation provides pain relief by disrupting the pain signals traveling between the spinal cord and the brain.
Neurostimulation devices include invasive and noninvasive approaches involving electrical stimulation to drive neural function within a circuit. The increased demand for internal neurostimulation devices is due to next-generation technological progressions in the neurostimulation devices, providing much-needed therapeutic relief to an unprecedented number of people affected by debilitating neurologic and psychiatric disorders worldwide. The rise of modern-day neuromodulation therapies has increased over half a century, rich with serendipitous discoveries and technological advances that have led to different neurostimulation strategies. Within the past two decades, innovation in medical device technology has begun to drive the evolution of these neurostimulation systems at a more accelerated pace
The convenient internal neurostimulation device used by the patients is vagus nerve stimulation. The vagus neurostimulation device uses a device to stimulate the vagus nerve with electrical impulses. An implantable vagus nerve stimulator is currently FDA-approved to treat epilepsy and depression. There's one vagus nerve on each side of the body, running from the brainstem through the neck to the chest and abdomen. In the future, software advancements such as closed-loop stimulation and remote programming will enable internal neurostimulation devices to be a more personalized and accessible technology. The future of internal neurostimulation devices is expected to improve quality of life further.
Asia-Pacific Internal Neurostimulation Devices Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints and challenges. All of this is discussed in detail below:
Drivers
- Rise In Prevalence And Incidence Of Neurological Disorders
Devices have the capacity building in the institution and the intended outputs and outcomes. Around one in six of the world's population suffer from neurological disorders, including Alzheimer's disease, Parkinson's disease, dementia, epilepsy and migraine. The prevalence of major incapacitating neurological disorders increases with age. Hence, governments worldwide face rising demand for treatment, rehabilitation and support services for neurological disorders.
For instance,
- In 2019, in India, the data by Neurology India stated that the common neurological disorders are stroke (37.9%), followed by headache disorder (17.5%), epilepsy (11.3%) and cerebral palsy (5.7%)
As the companies are constantly engaged in research and developmental activities, the knowledge about the prevalence and incidence of neurodegenerative diseases would help find novel solutions and aid in more collaborations and partnerships with market players in the U.S., Europe and Asia-Pacific region. This signifies the increase in research and development-related investments for the discovery and development of advanced, pain-free internal neurostimulation devices, which is expected to boost market growth.
- Demand For Internal Neurostimulation Devices As An Add On Therapy
Treating neurological pain may include pharmacological pain, physiotherapeutic and invasive methods. A considerable number of patients do not achieve sufficient pain relief with pharmacotherapy; in these patients with neuropathic pain, electrical neurostimulation may be applied.
For instance,
- The vagus nerve stimulation therapy (VNS) by LivaNova PLC. is a neuromodulator treatment designed for people with drug-resistant epilepsy four years of age and older with partial onset seizures. It can safely lead to fewer and shorter seizures and better recovery after seizures
The awareness about the early treatment of neurological syndrome and the use of internal neurostimulation devices would result in market players collaborating with health institutions to supply and distribute the devices. This will result in a rise in product and business line expansion. Hence, awareness among people about the timely treatment and use of internal neurostimulation devices is expected to drive market growth.
Opportunities
- Strategic Initiatives by Market Players
The demand for internal neurostimulation devices is increasing in the market owing to the increased levels of research and development along with the growth of the internal neurostimulation devices market aided by the desire for innovative medications. Thus, the top market players have implemented a new strategy by developing new devices and equipment, collaborating with other players in the market and improving business operations and profitability.
For instance,
- In January 2021, Boston Scientific began shipping their Wave Writer Alpha spinal line trigger frameworks to the U.S.
- In May 2019, Abbott Laboratories partnered with NIH on the BRAIN (Brain Research through Advancing Innovative Neurotechnologies) initiative to accelerate advancements in neurological science
Thus, the companies operating globally in the neurostimulation devices market are adopting collaboration to increase their product portfolio with advanced technology-rich products to boost their business in various dimensions. Thus, strategic initiatives by key market players are expected to offer significant opportunities for the market players operating in the Asia-Pacific internal neurostimulation devices market.
- Recent Product Developments in The Internal Neurostimulation Devices
The growth curve for the Asia-Pacific internal neurostimulation devices market is following an upward trend due to the demand for effective neurovascular therapies is steadily increasing due to the increasing prevalence of neurovascular diseases (such as epilepsy, brain stroke and cerebral aneurysm) and the severity of diseases (such as discharge and surrounding disorders) in target patients. Due to the rising prevalence and increasing awareness about the seriousness of these diseases, various equipment or devices are manufactured or are under clinical trials.
- In July 2022, NeuraLace announced FDA clearance of its external peripheral nerve stimulation system to relieve neuropathic pain
- In December 2020, Motility Medical announced a clinical trial of a transcutaneous abdominal stimulator in patients with chronic constipation, including from spinal cord injury
The clinical trials and product development in recent years have shown the potential of these technologies and the companies working in this market are trying to get the more advanced product in the market which will act as an opportunity for the market and propel the market in the forecast period.
Restraints/Challenges
- Risks Associated With The Implantation Of These Devices
Medical implants carry several hazards, including those related to surgery during installation or removal, infection and implant failure. The materials used in implants can potentially cause responses in some persons. Every surgical procedure carries some risk. These include bruising, discomfort, swelling and redness at the surgery site. Thereby will proportionally hamper the growth of implant devices. The increasing awareness about the rising risks related to neurostimulation implants, therefore, may hamper the market's growth.
For instance,
- Implant failure
- Surgical risks during placement or removal.
- Risk of implantable device hijacking.
- Rising infections
- Materials used in implants might show adverse reactions in patients
The risks mentioned above may hamper the growth of the internal neurostimulation devices market as the risks concerned with the patients are of keen importance. Thus, the awareness of the potential risks of implantable devices acts as a challenge for the Asia-Pacific internal neurostimulation devices market.
Lack Of Skilled Healthcare Professionals
Neurostimulation devices are implantable, programmable medical devices that deliver electrical stimulation to specific parts of the patient's brain, spinal cord, or peripheral nervous system to help treat various conditions, including chronic pain, movement disorders, epilepsy and Parkinson's disease. These powerful technologies require a high-cost developmental procedure and skilled professionals to handle sensitive devices. The estimated cost for the neurostimulation devices is approximately USD 22,970 which is 1,827,200.33 Indian Rupees. The replacement should be done every 3-6 years after implantation, which is a cost burden and is typically out of pocket for most patients.
Only a relatively small number of patients in poorer nations can afford neurological therapy due to high prices, a weak reimbursement environment and a lack of skilled healthcare resources. As a result, healthcare facilities are hesitant to spend money on novel or cutting-edge technology, limiting the expansion of the internal neurostimulation market. Thus, these challenges may hamper the growth of the market.
COVID-19 Impact on the Asia-Pacific Internal Neurostimulation Devices Market
During the pandemic, the Asia-Pacific internal neurostimulation devices market focused on using a combination of biology and information technology. During the COVID-19 pandemic, new therapeutic challenges have been added to the usual ones in the internal neurostimulation devices. Patients with an implantable device for intrathecal infusion need a refill of the pump to avoid abstinence syndrome. Patients with neurostimulation implants can need checkups in case of infection, wound dehiscence, or lead migration.
Recent Developments
- In January 2022, Medtronic received product approval from the Food and Drug Administration (FDA) for Intellis rechargeable neurostimulator, a spinal cord stimulation therapy for treating chronic pain resulting from diabetic peripheral neuropathy. The product approval received resulted in the addition of a new product in the spinal cord stimulation product category. The approval is expected for post-market approval in the U.S. market
- In July 2022, Abbott received approval from the Food and Drug Administration (FDA) for the Infinity deep brain stimulation system to treat depression. The approval received resulted in the rise in the initiation of pre and post-marketing approval and the addition of a new product to the product portfolio
Asia-Pacific Internal Neurostimulation Devices Market Scope
Asia-Pacific internal neurostimulation devices market is categorized into product type and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Spinal Cord Stimulation (SCS)
- Deep Brain Stimulation
- Vagus Nerve Stimulation
- Sacral Nerve Stimulation
- Gastric Electric Stimulation
On the basis of product type, the Asia-Pacific internal neurostimulation devices market is segmented into spinal cord stimulation (SCS), deep brain stimulation, vagus nerve stimulation, sacral nerve stimulation, gastric electric stimulation.
Distribution Channel
- Direct Tender
- Third Party Service Provider
On the basis of distribution channel, the Asia-Pacific internal neurostimulation devices market is segmented into direct tender and third party service provider.
Asia-Pacific Internal Neurostimulation Devices Market Regional Analysis/Insights
Asia-Pacific internal neurostimulation devices market is analysed, product type and distribution channel, as referenced above.
Some countries covered in the Asia-Pacific internal neurostimulation devices market are China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and the Rest of Asia-Pacific. China is expected to dominate the market due to rise in research and development activity and integrated internal neurostimulation device requirements in proteomic, genomic and clinical diagnostics, combined with the surging demand for advanced neurostimulation devices in the treatment of chronic pain management.
The country section of the report also provides individual market-impacting factors and changes in regulations in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands impact sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Asia-Pacific Internal Neurostimulation Devices Market Share Analysis
Asia-Pacific internal neurostimulation devices market competitive landscape provides details on the competitor. Details include company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, the Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth and application dominance. The above data points provided are only related to the companies' focus related to the Asia-Pacific internal neurostimulation devices market.
Some of the major players operating in the Asia-Pacific internal neurostimulation devices market are Medtronic, LivaNova PLC, Abbott, Microsemi (a subsidiary of Microchip Technology Inc.), Boston Scientific Corporation, Integer Holdings Corporation, GIMER Medical, Bionic Vision Technologies., NEVRO CORP., Valencia Technologies, CIRTEC, Sequana Medical NV, BIOINDUCTION, ONWARD, Axonics, Inc., among others.
SKU-